Anxiety Disorder Treatment market Research Report Covers, Future Trends, Past, Present Data and Deep Analysis 224 W 35TH ST STE 500, NY, UNITED STATES, November 13, 2024 /EINPresswire / -- The global ...
Atai plans to begin a Phase 2 study by the end of 2024 to evaluate VLS-01's safety, efficacy and durability in TRD patients. EMP-01 for Social Anxiety Disorder: EMP-01 is an oral R-MDMA formulation ...